Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Wheezes Clear all
Terminated Phase 1Phase 2 Interventional

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

NCT01025648
View directory record Official record
Conditions
Asthma
Interventions
E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Jose, California • Stockton, California
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

NCT01959412
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Treatment of Persistent Wheezing in Infants and Children

NCT00301171
View directory record Official record
Conditions
Asthma, Respiratory Sounds
Interventions
Inhaled Fluticasone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 36 Months
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

NCT02911935
View directory record Official record
Conditions
Respiratory Syncytial Virus, Bronchiolitis
Interventions
Oral azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

NCT00144846
View directory record Official record
Conditions
Asthma
Interventions
albuterol sulfate inhalation aerosol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 23 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
27
States / cities
Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 18, 2026, 10:35 PM EDT
Not listed No phase listed Observational

Clinical Validation of Omron WheezeScan

NCT04144699
View directory record Official record
Conditions
Asthma in Children, Bronchitis, Bronchiolitis
Interventions
Not listed
Lead sponsor
Omron Healthcare Co., Ltd.
Industry
Eligibility
3 Months to 8 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Chamblee, Georgia • Chicago, Illinois • Joliet, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 18, 2026, 10:35 PM EDT
Completed No phase listed Observational

A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma

NCT02163096
View directory record Official record
Conditions
Benign Joint Hypermobility Syndrome, Wheezing, Asthma
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 16 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

NCT01995175
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nasal swab sampling, Blood sampling, Diary cards
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 6 Years
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
9
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 18, 2026, 10:35 PM EDT
Completed No phase listed Observational

A 24 Month Observational Study of Infants 3-24 Months, Who Suffer an Acute Episode of Respiratory Infection and Wheezing Illness

NCT03741322
View directory record Official record
Conditions
Respiratory Tract Infections, Wheezing
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
3 Months to 24 Months
Enrollment
5 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 18, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study

NCT05667701
View directory record Official record
Conditions
Wheezing, Asthma in Children
Interventions
Soy isoflavone, matching placebo
Drug
Lead sponsor
Rajesh Kumar
Other
Eligibility
2 Months to 12 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Completed No phase listed Observational

Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants

NCT06424795
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
3 Days to 10 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 18, 2026, 10:35 PM EDT
Completed No phase listed Observational

Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing

NCT01452945
View directory record Official record
Conditions
Wheezing, Bronchiolitis
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 24 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Exploring a Cessation Intervention for Smokers

NCT01728038
View directory record Official record
Conditions
Asthma
Interventions
Cessation Counseling
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

NCT01255709
View directory record Official record
Conditions
Asthma
Interventions
Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 18, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581
View directory record Official record
Conditions
Asthma
Interventions
PF-07275315, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 18, 2026, 10:35 PM EDT
Enrolling by invitation Phase 3 Interventional

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315
View directory record Official record
Conditions
Wheezing, Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Montelukast for Early Life Wheezing

NCT00115297
View directory record Official record
Conditions
Lung Diseases, Asthma
Interventions
Montelukast, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
3 Months to 3 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 18, 2026, 10:35 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis

NCT01486758
View directory record Official record
Conditions
RSV Bronchiolitis
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 18, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 18, 2026, 10:35 PM EDT
Terminated No phase listed Observational

Chest Ultrasound of ER Patients With Cough or SOB

NCT02269761
View directory record Official record
Conditions
Cough, Dyspnea, Wheezing
Interventions
Nuvis Diagnostic Ultrasound System
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 18, 2026, 10:35 PM EDT
Completed No phase listed Observational

Vitamin C Supplementation to Pregnant Smokers: Follow-up of 2 Randomized Trials Plus Changes in DNA Methylation

NCT03206710
View directory record Official record
Conditions
Asthma, Wheezing, In Utero Nicotine, Pulmonary Function
Interventions
No current intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Months to 11 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

NCT00801853
View directory record Official record
Conditions
Asthma
Interventions
Aerovant, placebo
Drug · Other
Lead sponsor
Aerovance, Inc.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Acetaminophen Versus Ibuprofen in Children With Asthma

NCT01606319
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 59 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 18, 2026, 10:35 PM EDT